Table of Contents
What changed
Revenue from continuing operations rose 19.0% to NZ$100.2m, profit before tax jumped 209.3% to NZ$8.5m, and NPAT lifted 236.2% to NZ$6.6m. The company also cites underlying EBITDA of NZ$14.9m (+41%), although no GAAP group EBITDA line is disclosed. Operating cash flow nearly doubled to NZ$13.3m, gross borrowings fell 9.1% to NZ$66.6m, and cash rose to NZ$3.0m from NZ$0.1m, taking net debt to roughly NZ$63.7m from NZ$73.2m. The interim dividend was lifted 53.8% to 1.0cps (fully imputed).
What matters
- Leverage reset. Net debt to underlying EBITDA improved from about 6.9x to 4.3x in a single half, driven both by EBITDA growth and an absolute NZ$6.6m reduction in gross borrowings. For a thinly capitalised aged-care operator (equity of NZ$69.6m on assets of NZ$356.0m), this is the most consequential development.
- Operating leverage is showing. A 19.0% revenue lift converted into a 41% rise in underlying EBITDA and a tripling of PBT, consistent with a fixed-cost care base being spread over higher occupancy or pricing. The release flags EBITDAR per bed of NZ$29.9k on a rolling 12-month basis versus NZ$27.9k for FY25.
- Tax distortion inflates the NPAT headline. The effective tax rate fell to 22.3% from 28.6%, so NPAT growth of 236.2% overstates the operating read. PBT growth of 209.3% is the cleaner comparison and is still very strong.
Expectations
No numerical guidance, forward-work balance, or formal target was supplied. The seasonality shape is informative: in FY25, HY25 delivered 48% of full-year revenue but only 28% of full-year NPAT, indicating a second-half-weighted earnings profile. Annualising HY26 revenue gives roughly NZ$200.4m, about 14.4% above FY25 revenue of NZ$175.3m. If the second-half skew persists, full-year earnings would materially exceed FY25 NPAT of NZ$7.0m, but the release does not commit to that shape.
Quality of result
The result looks operationally driven rather than timing-assisted. Operating cash flow of NZ$13.3m represents 89.4% of underlying EBITDA (up from 62.3%), and pre-lease free cash flow rose to about NZ$9.6m from NZ$3.7m despite capex stepping up to NZ$3.7m. Receivable days tightened from 26.7 to 22.9 and inventory days stayed flat at roughly 1.1, so working capital did not flatter earnings. The 1.0cps interim dividend represents a 44.8% payout on NPAT (versus 94.2% prior) and 31% of pre-lease FCF, so distribution is comfortably covered. Two caveats: underlying EBITDA is non-GAAP and not fully reconciled in the supplied extract, and the lower effective tax rate accounts for roughly 27pp of the NPAT-over-PBT growth gap.
Unresolved
- What drove the effective tax rate down to 22.3%, and is the new rate sustainable?
- How much of the 19.0% revenue lift was occupancy, price, acquired beds, or mix, and how durable is the EBITDAR-per-bed uplift?
- What is the reconciliation between underlying EBITDA of NZ$14.9m and reported GAAP earnings, and are there non-recurring adjustments below the EBITDA line in HY26?
- With net debt still at NZ$63.7m and capex rising, what is the intended pace of further deleveraging versus village development spend?
This briefing cannot assess valuation, occupancy trajectory, regulatory funding settings, or management's unstated internal targets from the supplied materials.
Key metrics
| Metric | HY26 | HY25 | Change |
|---|---|---|---|
| Revenue | $100.2m | $84.2m | +19.0% ↑ |
| EBITDA | — | $10.6m | — |
| Net profit after tax | $6.6m | $2m | +236.2% ↑ |
| Net cash inflow from operating activities | $13.3m | $6.6m | +101.6% ↑ |
| Interim dividend per share | 1.0c | 0.7c | +53.8% ↑ |
| Profit before tax | $8.5m | $2.8m | +209.3% ↑ |
| Cash and cash equivalents | $3m | $0.07m | +4401.5% ↑ |
| Total assets | $355.9m | $330.5m | +7.7% ↑ |
Analytical metrics
| Metric | HY26 | HY25 | Context |
|---|---|---|---|
| PBT growth | +209.3% | — | cleaner earnings measure |
| Effective tax rate | 22.3% | 28.6% | — |
| OCF / EBITDA (cash conversion) | 89.4% | 62.3% | stable |
| FCF pre-lease | $9.6m | $3.7m | +$5.9m |
| FCF / NPAT | 144.9% | 188.8% | complementary conversion metric |
| Capex % revenue | 3.7% | 3.4% | — |
| Capex | $3.7m | −$2.9m | +$6.6m |
| Debtor days | 22.9 | 26.7 | -3.8 days |
| Inventory days | 1.1 | 1.3 | -0.2 days |
| Operating working capital | $13.2m | $13m | +$0.27m absorbed |
| Trade debtors | $12.6m | $12.4m | +$0.26m |
| Net debt | $63.7m | $73.2m | −$9.5m |
| Net debt / EBITDA | 4.30x | 6.90x | Strengthening |
| Gross borrowings | $66.6m | $73.3m | −$6.6m |
| Payout ratio vs NPAT | 44.8% | — | — |
| Payout ratio vs FCF pre-lease | 31.0% | — | covered |
| ROE (annualised) | 9.5% | 3.1% | Strengthening |
| HY25 share of FY25 revenue | 48.0% | — | Other half was 52.0% |
| HY25 share of FY25 NPAT | 28.0% | — | Other half was 72.0% |
| Profit from continuing operations | $6.6m | $2m | +$4.7m |
This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.